An interventional study of Cholecalciferol in Vitamin D, Insulin Resistance and Obesity, Childhood, sponsored by Coordinación de Investigación en Salud, Mexico. Recruiting at 1 site in Mexico. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Coordinación de Investigación en Salud, Mexico · Not applicable, Interventional, and Treatment
Among 27 studies testing cholecalciferol in Insulin Resistance — 1 open to participants now, 1 under way, none of them phase 3. Cholecalciferol · Insulin Resistance.
Among the 27 studies testing cholecalciferol in Insulin Resistance, this one is the 19th largest by planned enrollment, is the only one that started in 2025, is one of 15 with no phase, and was the 27th registered.
2,969 studies on the registry are indexed under Insulin Resistance; 338 are open to participants now.
Browse Insulin Resistance studies →1 of the 27 studies testing cholecalciferol in Insulin Resistance is open now, in 1 country.
By country, each count listing its studies:
Cholecalciferol: first FDA approval 2000 (INFUVITE ADULT), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 244 Insulin Resistance studies recruiting now, 54 (22%) set no upper age limit and 158 (65%) stop at 75 or younger; 30 take children under 18; 113 take healthy volunteers.
This study: 10 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 40 is close to the median of 40 across 2,369 interventional studies indexed under Insulin Resistance.
Median enrollment 84 across the 27 interventional studies. Of the 23 that completed or were terminated, 6 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 27 has an industry lead sponsor. The 10 most frequent:
Coordinación de Investigación en Salud, Mexico is the lead sponsor of 98 studies on the registry; 16 are open to participants now.
Coordinación de Investigación en Salud, Mexico has 6 studies filed under Insulin Resistance — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing cholecalciferol in Insulin Resistance, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Introduction: Vitamin D deficiency is commonly observed in patients with obesity, primarily due to sequestration by adipose tissue. Recent research highlights the importance of this deficiency, showing a correlation between low vitamin D levels and mechanisms contributing to insulin resistance.
Objectives: This study aims to compare the effects of supplementing with 4,000 IU of vitamin D versus 1,000 IU over six months on insulin resistance and the leptin/adiponectin ratio in school-aged children and adolescents with obesity.
Materials and Methods: A controlled clinical trial will be conducted involving 40 children with obesity aged 10 to 18 years (BMI >95th percentile). Participating children and their parents will undergo measurements such as weight, height, BMI, body fat, and Tanner stage. All participants will receive dietary and physical activity recommendations based on WHO guidelines. After initial assessments, participants will be randomly assigned to receive either 4,000 IU or 1,000 IU of vitamin D. They will be monitored monthly for capsule intake and adverse effects, with follow-up measurements of anthropometry, leptin, adiponectin, insulin \& lipid profile.
Statistical Analysis: Baseline characteristics will be compared using t-Student or U-Mann Whitney tests, depending on variable distribution. The intervention's impact will be assessed by calculating deltas for body fat and biochemical measurements, with significance tested using paired t-tests or Wilcoxon tests. Covariance analysis (ANCOVA) will be used to adjust for confounding variables.
Materials and Methods The study will compare the effect of 4000 IU vitamin D supplementation over six months on adipokines (leptin/adiponectin ratio) and insulin resistance (HOMA index) in school-aged children and adolescents with obesity, against a similar group receiving 1000 IU of vitamin D. The study will be conducted at the Hospital Infantil de México Federico Gómez and UMAE Hospital de Pediatría, Centro Médico Nacional Siglo XXI. This controlled clinical trial features an experimental, randomized, double-blind design. The study population includes schoolchildren with obesity attending the Adolescent Clinic at Hospital Infantil de México and outpatient services at UMAE Hospital de Pediatría.
Sampling and Selection Criteria A non-probabilistic sampling will select children identified with obesity. Selection criteria include both male and female patients aged 10 to 18 with obesity as per BMI (>95th percentile according to WHO age and sex tables), who agree to participate, and reside in Mexico City. Exclusion criteria exclude patients with comorbidities unrelated to obesity, genetic syndromes, those currently receiving vitamin supplements or pharmacological treatments for obesity, and those with pre-existing insulin resistance requiring pharmacological treatment.
Treatment Arms Group A will receive 4000 IU of vitamin D daily for six months. Group B, the control group, will receive 1000 IU daily. Randomization is managed using a software tool, with treatment assignments sealed in opaque envelopes and administered according to randomized allocation.
Sample Size and Statistical Analysis Sample size calculations for unpaired group comparisons anticipate 20 participants per group, adjusting for a 20% dropout rate, based on differences in the leptin/adiponectin ratio and HOMA index. Statistical analyses will be performed on both an intention-to-treat and per-protocol basis. Descriptive analysis will evaluate quantitative variables' distribution using the Kolmogorov-Smirnov test to determine appropriate statistical tests. Comparative analyses will utilize t-tests or U-Mann Whitney tests for quantitative variables, and chi-squared or Fisher's exact tests for categorical data. Mixed-effects regression models will assess changes in dependent variables over time. Analyses will be conducted using Stata version 14.0, with a confidence level of ≤0.05.
Procedures and Follow-Up Prior to the intervention, patients will undergo comprehensive assessments including anthropometry and blood tests. Dietary and physical activity plans will be provided, tailored to each patient's caloric needs and physical capabilities. Monthly follow-ups will ensure adherence to the supplementation regimen and monitor any adverse effects. The final assessment will repeat all initial evaluations to assess changes after six months of treatment.
Blinding and Data Integrity The study ensures blinding for medical staff, patients, families, and data collectors. The treatment capsules for both groups will be identical in appearance to maintain blinding integrity throughout the trial.
Study Conclusion The study concludes with a final collection of anthropometric and blood sample data after six months, which will be analyzed to determine the effectiveness of vitamin D supplementation on improving insulin resistance and adipokine levels among children and adolescents with obesity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4000 IU daily orally during six months.
Dietary Supplement: Cholecalciferol
1000 IU daily orally during six months. .
Dietary Supplement: Cholecalciferol
cholecalciferol 4000 IU daily orally
Also known as: Vitamin D
Change from Baseline in 25 hydroxi vitamin D at 6 Months.
A peripheral blood sample will be collected. Patients are required to fast for 12 hours prior to presenting for blood sample collection, scheduled between 7:00 and 8:00 AM. Blood will be drawn via venipuncture and subsequently centrifuged at 3000 revolutions per minute for five minutes to separate the serum. The serum will be aliquoted and stored at -20 degrees Celsius until further analysis. The levels of 25-hydroxy Vitamin D will be quantified using an ELISA method, employing the 6913 25(OH) Vitamin D ELISA Kit (96 Tests - Abcam) in conjunction with the Varioskan™ LUX multimode microplate reader. At the end of the six-month study, a second blood sample will be collected to assess vitamin D levels at that time. Vitamin D Concentration Standards: Normal: Greater than 30 ng/mL Insufficiency: 20-30 ng/mL Deficiency: Less than 20 ng/mL
Time frame: From enrollment to the end of treatment at 6 months
Change from Baseline in leptin at 6 Months.
A sample of peripheral blood will be collected to measure serum levels of leptin. Patients are required to fast for 12 hours and should arrive for the sample collection between 7:00 and 8:00 AM. The blood will be drawn through venipuncture. After collection, the sample will be centrifuged at 3000 revolutions per minute for five minutes. The serum will then be aliquoted for subsequent analyses. These serum samples will be stored at -20 degrees Celsius until they are analyzed. Leptin will be measured using the ELISA technique with the commercial kit from Merck Millipore, Milliplex Map Human Adipokine Magnetic Bead Panel Endocrine Multiplex Assay. At the end of the six-month study, a second blood sample will be collected to assess leptin levels at that time.
Time frame: From enrollment to the end of treatment at 6 months
Change from Baseline in adiponectin at 6 Months.
A sample of peripheral blood will be collected to measure serum levels of adiponectin. Patients are required to fast for 12 hours and should arrive for the sample collection between 7:00 and 8:00 AM. The blood will be drawn through venipuncture. After collection, the sample will be centrifuged at 3000 revolutions per minute for five minutes. The serum will then be aliquoted for subsequent analyses. These serum samples will be stored at -20 degrees Celsius until they are analyzed. Adiponectin will be measured using the ELISA technique with the commercial kit from Merck Millipore, Milliplex Map Human Adipokine Magnetic Bead Panel Endocrine Multiplex Assay. At the end of the six-month study, a second blood sample will be collected to assess adiponectin levels at that time.
Time frame: From enrollment to the end of treatment at 6 months
Change from Baseline in insulin at 6 Months.
Insulin is an anabolic hormone secreted by the pancreas that plays a role in regulating blood glucose level. A sample of peripheral blood will be collected to measure serum levels of insulin . Patients are required to fast for 12 hours and should arrive for the sample collection between 7:00 and 8:00 AM. The blood will be drawn through venipuncture. After collection, the sample will be centrifuged at 3000 revolutions per minute for five minutes. The serum will then be aliquoted for subsequent analyses. These serum samples will be stored at -20 degrees Celsius until they are analyzed. Insulin levels will be determined through the chemiluminescence technique using the Varioskan™ LUX multimode microplate reader. At the end of the six-month study, a second blood sample will be collected to assess insulin levels at that time.
Time frame: From enrollment to the end of treatment at 6 months
Change from Baseline in HOMA-IR at 6 Months.
The HOMA-IR index is utilized to evaluate the relationship between glucose and insulin, assessing insulin resistance. It is calculated using the formula: HOMA = (Glucose \* Insulin) / 405. At the end of the six-month study, At the end of the six-month study, the HOMA-IR index will be calculated again.
Time frame: From enrollment to the end of treatment at 6 months
Change from Baseline in triglycerides at 6 Months.
Triglycerides, a class of lipids, consist of one glycerol molecule bonded to three fatty acids. To determine triglyceride levels, a sample of peripheral blood will be collected from patients who must fast for 12 hours and arrive for sampling between 7:00 and 8:00 AM. The blood will be drawn through venipuncture, then centrifuged at 3000 revolutions per minute for five minutes, and the serum will be separated into aliquots for analysis. These samples will be stored at -20 degrees Celsius until tested. Triglyceride concentrations will be measured using a colorimetric method on the Varioskan™ LUX multimode microplate reader, an automated clinical chemistry analyzer. Triglyceride levels below 100 mg/dL in children under 10 years and below 130 mg/dL in individuals over 10 years are considered abnormal. At the end of the six-month study, a second blood sample will be collected to assess triglyceride levels at that time.
Time frame: From enrollment to the end of treatment at 6 months
Change from Baseline in HDL cholesterol at 6 Months.
High-density lipoprotein (HDL) cholesterol consists of smaller and denser lipoproteins, composed of a high proportion of proteins, and acts as a protective factor against cardiovascular disease. To determine HDL cholesterol levels, a peripheral blood sample will be collected from patients who are required to fast for 12 hours and arrive for sampling between 7:00 and 8:00 AM. Blood will be drawn through venipuncture, then centrifuged at 3000 revolutions per minute for five minutes. The serum will be separated into aliquots for subsequent analysis. These samples will be stored at -20 degrees Celsius until they are tested. HDL cholesterol levels will be measured using a colorimetric method on the Varioskan™ LUX multimode microplate reader, an automated clinical chemistry analyzer. Normal values are considered to \>40 mg/dL. At the conclusion of the six-month study, a second blood sample will be collected to reassess the HDL cholesterol levels.
Time frame: From enrollment to the end of treatment at 6 months
Change from Baseline in LDL cholesterol at 6 Months.
To determine Low-density lipoprotein (LDL) cholesterol, a peripheral blood sample will be collected from patients required to fast for 12 hours and arrive for sampling between 7:00 and 8:00 AM. Blood will be drawn via venipuncture and then centrifuged at 3000 revolutions per minute for five minutes. The serum will be separated into aliquots for subsequent analysis. These samples will be stored at -20 degrees Celsius until they are tested. LDL cholesterol levels will be measured using a colorimetric method on the Varioskan™ LUX multimode microplate reader, an automated clinical chemistry analyzer. Levels considered abnormal are \>130 mg/dL. At the end of the six-month study period, a second blood sample will be collected to reassess the LDL cholesterol levels.
Time frame: From enrollment to the end of treatment at 6 months
Change from Baseline in total cholesterol at 6 Months.
Total cholesterol is an essential molecule vital for life, performing crucial structural and metabolic functions in the human body. To measure total cholesterol levels, a peripheral blood sample will be collected from patients who must fast for 12 hours and arrive for sampling between 7:00 and 8:00 AM. Blood will be drawn through venipuncture, then centrifuged at 3000 revolutions per minute for five minutes. The serum will be separated into aliquots for further analysis. These samples will be stored at -20 degrees Celsius until they are tested. Total cholesterol levels will be determined using a colorimetric method with the Varioskan™ LUX multimode microplate reader, an automated clinical chemistry analyzer. Normal total cholesterol levels are considered to be less than 200 mg/dL. At the conclusion of the six-month study, a second blood sample will be collected to reassess total cholesterol levels.
Time frame: From enrollment to the end of treatment at 6 months
Change from Baseline in glucose at 6 Months.
Glucose is a vital molecule that provides energy to the body. To measure glucose levels, a peripheral blood sample will be collected from patients who must fast for 12 hours and arrive for sampling between 7:00 and 8:00 AM. Blood will be drawn through venipuncture, then centrifuged at 3000 revolutions per minute for five minutes. The serum will be separated into aliquots for further analysis. These samples will be stored at -20 degrees Celsius until they are tested. Glucose levels will be determined using a colorimetric method with the Varioskan™ LUX multimode microplate reader, an automated clinical chemistry analyzer. At the conclusion of the six-month study, a second blood sample will be collected to reassess glucose levels.
Time frame: From enrollment to the end of treatment at 6 months
Change from Baseline in The Body Mass Index at 6 Months.
The Body Mass Index (BMI): A measure of the relationship between an individual's weight and height. It will be determined using the formula: weight (kg) / height\^2 (m²). At the end of the six-month study, the BMI will be recalculated.
Time frame: From enrollment to the end of treatment at 6 months
Change in the Z-score of the Body Mass Index at 6 Months.
The Z-score of the Body Mass Index (BMI) is a statistical measurement that expresses the number of standard deviations a person's BMI is from the mean or average BMI of a population. This score is particularly useful in pediatric populations to assess how a child's body mass compares to that of their peers, considering age and gender. The calculation is based on national or global reference data that standardizes BMI according to age and sex. This standardized score helps to accurately identify and categorize underweight, healthy weight, overweight, and obesity in children and adolescents. At the start of the study, the BMI Z-score will be calculated to establish baseline levels for each participant. At the end of the six-month study period, the BMI Z-score will be recalculated to determine any changes.
Time frame: From enrollment to the end of treatment at 6 months
Change in the leptin/adiponectin ratio at 6 months
The leptin/adiponectin ratio represents the ratio of serum leptin to adiponectin levels. It will be determined through laboratory analysis after a 12-hour fasting period. Leptin and adiponectin will be measured using the ELISA technique with the commercial kit from Merck Millipore, Milliplex Map Human Adipokine Magnetic Bead Panel Endocrine Multiplex Assay.Following the 6-month study period, a second blood sample will be taken.
Time frame: From enrollment to the end of treatment at 6 months
Started Mar 2025 (actual). Primary completion is estimated for Sep 2025, 6 months after the start.
Of 714 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 6 months is below that.
Counting every sponsor, half of 754 studies reached it within 21 months; a quarter within 9 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cholecalciferol
Coordinación de Investigación en Salud, Mexico